Novartis Forecast, price target & analysts
Novartis Target price 2026 - Analyst rating & recommendation
Novartis Classifications & Recommendation
Novartis Price Target
| Target Price | CHF130.97 |
| Price | CHF124.70 |
| Potential | 5.03% |
| Number of Estimates | 27 |
| 27 Analysts have issued a price target Novartis 2027 . The average Novartis target price is CHF130.97. This is 5.03% higher than the current stock price. The highest price target is CHF157.50 26.30% , the lowest is CHF99.99 19.82% . | |
| A rating was issued by 34 analysts: 16 Analysts recommend Novartis to buy, 14 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2027 of 5.03% . Most analysts recommend the Novartis stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
29 Analysts have issued a sales forecast Novartis 2026 . The average Novartis sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
24 Analysts have issued an Novartis EBITDA forecast 2026. The average Novartis EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
30 Novartis Analysts have issued a net profit forecast 2026. The average Novartis net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
Current Novartis Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| LANDESBANK BADEN-WUERTTEMBERG |
Hold
➜
Hold
|
Unchanged | Sep 23 2026 |
| ROTHSCHILD & CO REDBURN |
Sell
➜
Sell
|
Unchanged | Sep 23 2026 |
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Sep 21 2026 |
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Sep 18 2026 |
| BAADER EUROPE / ALPHAVALUE |
Buy
➜
Buy
|
Unchanged | Sep 17 2026 |
| GUGGENHEIM SECURITIES LLC |
Neutral
➜
Neutral
|
Unchanged | Sep 09 2026 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Sep 08 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Hold
➜
Hold
|
Sep 23 2026 |
|
Unchanged
ROTHSCHILD & CO REDBURN:
Sell
➜
Sell
|
Sep 23 2026 |
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Sep 21 2026 |
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Sep 18 2026 |
|
Unchanged
BAADER EUROPE / ALPHAVALUE:
Buy
➜
Buy
|
Sep 17 2026 |
|
Unchanged
GUGGENHEIM SECURITIES LLC:
Neutral
➜
Neutral
|
Sep 09 2026 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Sep 08 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
